1. Home
  2. MAIA vs ALAR Comparison

MAIA vs ALAR Comparison

Compare MAIA & ALAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • ALAR
  • Stock Information
  • Founded
  • MAIA 2018
  • ALAR 2013
  • Country
  • MAIA United States
  • ALAR Israel
  • Employees
  • MAIA N/A
  • ALAR N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • ALAR Computer Software: Prepackaged Software
  • Sector
  • MAIA Health Care
  • ALAR Technology
  • Exchange
  • MAIA Nasdaq
  • ALAR Nasdaq
  • Market Cap
  • MAIA 46.7M
  • ALAR 41.3M
  • IPO Year
  • MAIA 2022
  • ALAR 2018
  • Fundamental
  • Price
  • MAIA $2.15
  • ALAR $7.26
  • Analyst Decision
  • MAIA
  • ALAR Strong Buy
  • Analyst Count
  • MAIA 0
  • ALAR 1
  • Target Price
  • MAIA N/A
  • ALAR $11.00
  • AVG Volume (30 Days)
  • MAIA 79.7K
  • ALAR 109.5K
  • Earning Date
  • MAIA 05-13-2025
  • ALAR 05-20-2025
  • Dividend Yield
  • MAIA N/A
  • ALAR N/A
  • EPS Growth
  • MAIA N/A
  • ALAR N/A
  • EPS
  • MAIA N/A
  • ALAR 0.08
  • Revenue
  • MAIA N/A
  • ALAR $31,824,000.00
  • Revenue This Year
  • MAIA N/A
  • ALAR $12.46
  • Revenue Next Year
  • MAIA N/A
  • ALAR $26.00
  • P/E Ratio
  • MAIA N/A
  • ALAR $8.75
  • Revenue Growth
  • MAIA N/A
  • ALAR 20.00
  • 52 Week Low
  • MAIA $1.40
  • ALAR $5.45
  • 52 Week High
  • MAIA $5.99
  • ALAR $46.69
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 70.43
  • ALAR 54.74
  • Support Level
  • MAIA $1.51
  • ALAR $6.86
  • Resistance Level
  • MAIA $1.61
  • ALAR $8.30
  • Average True Range (ATR)
  • MAIA 0.12
  • ALAR 0.60
  • MACD
  • MAIA 0.06
  • ALAR 0.18
  • Stochastic Oscillator
  • MAIA 90.91
  • ALAR 73.33

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

Share on Social Networks: